SOHO 2023 | Current treatments and sequencing of agents in multiple myeloma
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, gives an overview of a range of agents being investigated for the treatment of both relapsed/refractory (R/R) and frontline multiple myeloma, highlighting the importance of sequencing these agents in the best way. Dr Cerchione discusses many promising agents, including selinexor, pomalidomide, daratumumab, mezigdomide and melflufen, and highlights the settings where these agents are most beneficial. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
